Rutu Valapil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rutu Valapil has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- James E. Polli
Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, MD 21201, USA
2 shared publications - Alaa H. Abuznait1 shared publication
Alan F. Rawle
1 shared publication- Anabelle Ethier1 shared publication
- André O'REilly Beringhs
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut
1 shared publication - Anna Schwendeman
Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA
1 shared publication
Latest Publications
- Open Access
- 6 April 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Mastering particle size analysis: lessons, challenges, and future directions from the FDA–CRCG workshop
Particle-size distribution (PSD) measurement is a cornerstone of pharmaceutical development and regulatory assessment, influencing formulation stability, dissolution, product quality, and performance. Yet the seemingly straightforward nature of “size measurements” often conceals substantial scientific and practical complexity. To strengthen shared understanding and advance good measurement practices, the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) co-hosted a two-day hybrid workshop, “Mastering Particle Size Analysis: A Step-by-Step Illustration of Techniques and Best Practices,” held on September 23–24, 2025. The workshop brought together scientists from regulatory agencies, industry, academia, and instrument manufacturers to examine the principles, data interpretation, and analytical procedure robustness of two widely used techniques—Dynamic Light Scattering (DLS) and Laser Diffraction (LD). The program integrated scientific lectures, vendor-led demonstrations, and structured small-group discussions organized around real-world case studies. Prior to the workshop, participating vendors conducted independent characterization of five pre-workshop materials representing diverse formulation types, providing a shared baseline for comparison. In total, 2823 participants registered for the workshop, including 127 for in-person attendance and 2696 for virtual attendance from across the global pharmaceutical community. Of those that registered, 119 participants attended in-person, and 1464 attended virtually during the two days. Discussions throughout the workshop emphasized that PSD data cannot be interpreted in isolation because what is measured depends on the model assumption, sample condition, and analytical purpose. Participants concluded that reliable characterization demands “fit-for-purpose” analytical procedure design, transparent reporting, and a clear linkage between measurements and material function. Major outcomes included (i) recognition that methodological transparency outweighs pursuit of a single “true” particle size; (ii) identification of the dominant sources of inter-laboratory variability; and (iii) broad consensus on the need for harmonized terminology, validation criteria, and reporting expectations. The workshop closed with collective commitments to prepare a community white paper and to initiate an inter-laboratory study aimed at improving comparability of PSD data across techniques, platforms, and laboratories—steps that will help ensure measurement integrity and regulatory confidence in complex drug development.
- 6 April 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Open AccessMastering particle size analysis: lessons, challenges, and future directions from the FDA–CRCG workshop
Particle-size distribution (PSD) measurement is a cornerstone of pharmaceutical development and regulatory assessment, influencing formulation stability, dissolution, product quality, and performance. Yet the seemingly straightforward nature of “size measurements” often conceals substantial scientific and practical complexity. To strengthen shared understanding and advance good measurement practices, the U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) co-hosted a two-day hybrid workshop, “Mastering Particle Size Analysis: A Step-by-Step Illustration of Techniques and Best Practices,” held on September 23–24, 2025. The workshop brought together scientists from regulatory agencies, industry, academia, and instrument manufacturers to examine the principles, data interpretation, and analytical procedure robustness of two widely used techniques—Dynamic Light Scattering (DLS) and Laser Diffraction (LD). The program integrated scientific lectures, vendor-led demonstrations, and structured small-group discussions organized around real-world case studies. Prior to the workshop, participating vendors conducted independent characterization of five pre-workshop materials representing diverse formulation types, providing a shared baseline for comparison. In total, 2823 participants registered for the workshop, including 127 for in-person attendance and 2696 for virtual attendance from across the global pharmaceutical community. Of those that registered, 119 participants attended in-person, and 1464 attended virtually during the two days. Discussions throughout the workshop emphasized that PSD data cannot be interpreted in isolation because what is measured depends on the model assumption, sample condition, and analytical purpose. Participants concluded that reliable characterization demands “fit-for-purpose” analytical procedure design, transparent reporting, and a clear linkage between measurements and material function. Major outcomes included (i) recognition that methodological transparency outweighs pursuit of a single “true” particle size; (ii) identification of the dominant sources of inter-laboratory variability; and (iii) broad consensus on the need for harmonized terminology, validation criteria, and reporting expectations. The workshop closed with collective commitments to prepare a community white paper and to initiate an inter-laboratory study aimed at improving comparability of PSD data across techniques, platforms, and laboratories—steps that will help ensure measurement integrity and regulatory confidence in complex drug development.
- Open Access
- 9 January 2026
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 41 (6) , 330-338
Using error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans
Molnupiravir (MOV) is a prodrug of N-hydroxycytidine (NHC), an analog of the endogenous ribonucleoside cytidine that can be administered orally. MOV is used for treating patients infected by SARS-CoV-2, the coronavirus responsible for COVID-19. MOV and NHC are mutagenic in bacterial and in mammalian cell cultures, yet both chemicals have been negative or equivocal in nonclinical in vivo models of mutagenesis. We designed and validated a novel error-corrected sequencing (ECS) method for detecting single basepair substitutions in tissue samples obtained from genetically heterogeneous humans. The software used for this ECS method is available for free from a public online repository and it is suitable for analysis of in vivo and in vitro derived samples collected in various experimental scenarios. We recruited two groups of patients having COVID-19 1–3 years ago, one group that received a full course of MOV therapy and the other group (matched for age and COVID-19 diagnosis date) that did not receive MOV. Using the ECS method, we determined the frequencies of basepair substitutions in nucleated cells isolated from peripheral blood of the patients. There was no observed difference in the frequency of mutations, the types of mutations, or mutational spectra between the MOV and the control groups. Also, the spectra of mutations in the MOV group did not show any evidence of the mutational signature expected from exposures to MOV or NHC based on data from mammalian cell culture models. Within the limits of this study, the dose of MOV authorized for the treatment of COVID-19 under emergency use authorization appears to have no mutational consequences for treated patients.
- 9 January 2026
- Published by Oxford University Press (OUP) in Mutagenesis
- Vol. 41 (6) , 330-338
Open AccessUsing error-corrected sequencing for evaluating mutagenicity of molnupiravir in humans
Molnupiravir (MOV) is a prodrug of N-hydroxycytidine (NHC), an analog of the endogenous ribonucleoside cytidine that can be administered orally. MOV is used for treating patients infected by SARS-CoV-2, the coronavirus responsible for COVID-19. MOV and NHC are mutagenic in bacterial and in mammalian cell cultures, yet both chemicals have been negative or equivocal in nonclinical in vivo models of mutagenesis. We designed and validated a novel error-corrected sequencing (ECS) method for detecting single basepair substitutions in tissue samples obtained from genetically heterogeneous humans. The software used for this ECS method is available for free from a public online repository and it is suitable for analysis of in vivo and in vitro derived samples collected in various experimental scenarios. We recruited two groups of patients having COVID-19 1–3 years ago, one group that received a full course of MOV therapy and the other group (matched for age and COVID-19 diagnosis date) that did not receive MOV. Using the ECS method, we determined the frequencies of basepair substitutions in nucleated cells isolated from peripheral blood of the patients. There was no observed difference in the frequency of mutations, the types of mutations, or mutational spectra between the MOV and the control groups. Also, the spectra of mutations in the MOV group did not show any evidence of the mutational signature expected from exposures to MOV or NHC based on data from mammalian cell culture models. Within the limits of this study, the dose of MOV authorized for the treatment of COVID-19 under emergency use authorization appears to have no mutational consequences for treated patients.